Sign in
Taking peoplePhase 4

Heartburn, Gastroesophageal Reflux Disease

Key facts

Who runs it
Incheon St.Mary's Hospital
Where
South Korea10 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
160 people, planned
Started
7 Jul 2025
Planned end
30 Sept 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Zastaprazan
  • Esomeprazole
Record updated
23 December 2025

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Korean adults aged 19 years or older as of the date of written consent
  • Those diagnosed with erosive gastroesophageal reflux disease based on upper gastrointestinal endoscopy (EGD)
  • Those who reported nighttime heartburn for more than 3 months at the time of screening (Visit 1)
  • Those who voluntarily decided to participate and provide written informed consent

Who cannot take part

  • Individuals who have received other investigational products within one month prior to the screening visit (Visit 1)
  • Individuals with a history of drug or alcohol abuse (within the past year)
  • Those who cannot undergo upper gastrointestinal endoscopy (EGD)
  • In addition to the above, individuals with clinically significant findings that the investigator deems medically inappropriate for the present study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation.

Read full original descriptionShow less

GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life.

This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).

The 2 groups in the trial

  • ZastaprazanTreatment being tested

    Zastaprazan 20 mg, once daily, preferably administered orally in the morning before breakfast for four weeks

  • EsomeprazoleExisting treatment, for comparison

    Esomeprazole 40 mg, once daily, preferably administered orally in the morning before breakfast for four weeks

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Double-blind, Randomized, Investigator-initiated Trial to Evaluate the Degree of Symptom Relief of Zastaprazan and Esomeprazole in Patients With Erosive Reflux Disease With Night-time Heartburn Symptoms
Record updated
23 December 2025